The FDA has granted fast track designation to the investigational therapeutic agent WTX-124 for the potential treatment of ...

Patients in the no LND arm had shorter surgery duration, less blood loss, and reduced postoperative hospital stay compared to ...

A new study explores strategies to enhance survival rates for patients facing challenges in finding bone marrow donors, advocating for quicker alternative options. Stephanie Lee, MD, MPH, professor ...

Cemiplimab significantly improved disease-free survival in high-risk CSCC, reducing recurrence or death risk by 68% compared ...

The FDA has issued a complete response letter (CRL) to a new drug application (NDA) for Dasynoc for the treatment of chronic ...

During a live event, Claudine Isaacs, MD, discussed using elacestrant for hormone receptor–positive, HER2-low metastatic ...

NBTXR3 combined with radiotherapy and ICIs showed a 47.4% objective response rate and 78.9% disease control rate in melanoma ...

In recognition of October as Breast Cancer Awareness Month, Sarah Premji, MD, assistant director of Breast Cancer Research at Sarah Cannon Research Institute (SCRI), discusses exciting advancements in ...

Active surveillance (AS) appears to be a durable and safe long-term management strategy for patients with small, low-risk papillary thyroid cancer (PTC), with durability and age strongly correlated, ...

Casdatifan activates hundreds of genes in response to low oxygen levels, and when oxygen levels return to normal, HIF-2a is ...

Cintredekin besudotox targets IL-12 alpha-2 receptor-expressing tumor cells, using convection-enhanced delivery to bypass the ...

The TROPION-Breast02 trial is the first to show overall survival benefit in this patient population, indicating a potential ...